JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Inicio・Lista de Acciones・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Cerrado

SectorSalud

34.93 0.03

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

34.11

Máximo

35.14

Métricas clave
By Trading Economics
Ingresos	-19M -213M
BPA	-1.13
Margen de beneficio	-74.379
Empleados	616
EBITDA	-24M -237M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+94.67% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-659M 6.9B
Apertura anterior	34.9
Cierre anterior	34.93

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

41 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

40.67 / 41.96 Soporte y Resistencia

REVOLUTION Medicines Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 ago 2025, 17:49 UTC

Principales Movimientos del Mercado

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 ago 2025, 17:18 UTC

Principales Movimientos del Mercado

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 ago 2025, 16:25 UTC

Ganancias

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 ago 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

11 ago 2025, 23:42 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

11 ago 2025, 23:42 UTC

Charlas de Mercado

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 ago 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 ago 2025, 23:32 UTC

Charlas de Mercado

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 ago 2025, 23:02 UTC

Charlas de Mercado

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 ago 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

11 ago 2025, 20:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 ago 2025, 20:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 ago 2025, 20:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement 2Q Rev $25.8M >EXOD

11 ago 2025, 20:14 UTC

Charlas de Mercado

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 ago 2025, 19:12 UTC

Charlas de Mercado

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 ago 2025, 18:56 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 ago 2025, 18:31 UTC

Charlas de Mercado

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 ago 2025, 17:43 UTC

Charlas de Mercado

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 ago 2025, 17:28 UTC

Charlas de Mercado

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 ago 2025, 17:16 UTC

Charlas de Mercado

Commodity Longs Fall to 11-Month Low -- Market Talk

11 ago 2025, 16:42 UTC

Adquisiciones, fusiones, absorciones

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 ago 2025, 16:27 UTC

Adquisiciones, fusiones, absorciones

BBVA Says Sabadell Offer Remains in Effect

11 ago 2025, 16:26 UTC

Adquisiciones, fusiones, absorciones

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 ago 2025, 16:25 UTC

Adquisiciones, fusiones, absorciones

Banco de Sabadell Announced TSB Sale on July 1

11 ago 2025, 16:25 UTC

Adquisiciones, fusiones, absorciones

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparación entre iguales

Cambio de precio

REVOLUTION Medicines Inc Esperado

Precio Objetivo

By TipRanks

94.67% repunte

Estimación a 12 meses

Media 67.55 USD 94.67%

Máximo 80 USD

Mínimo 37.91 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

40.67 / 41.96Soporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

41 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.